Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options.

Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM.

Clin Immunol. 2019 Dec;209:108274. doi: 10.1016/j.clim.2019.108274. Epub 2019 Oct 31. Review.

PMID:
31678365
2.

cAMP Response Element Modulator α Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus.

Hofmann SR, Mäbert K, Kapplusch F, Russ S, Northey S, Beresford MW, Tsokos GC, Hedrich CM.

J Immunol. 2019 Oct 25. pii: ji1900760. doi: 10.4049/jimmunol.1900760. [Epub ahead of print]

PMID:
31653682
3.

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.

Davies R, Cock D, Kearsley-Fleet L, Southwood T, Baildam E, Beresford MW, Foster HE, Thomson W, Ramanan A, Hyrich KL; British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) and the Biologics for Children with Rheumatic Diseases (BCRD) study.

Rheumatology (Oxford). 2019 Oct 12. pii: kez449. doi: 10.1093/rheumatology/kez449. [Epub ahead of print]

PMID:
31605484
4.

The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial.

Rooney M, Bishop N, Davidson J, Beresford MW, Pilkington C, Donagh JM, Wyatt S, Gardner-Medwin J, Satyapal R, Clinch J, Foster H, Elliott M, Verghis R; British Society for Paediatric and Adolescent Rheumatology UK.

EClinicalMedicine. 2019 Jul 3;12:79-87. doi: 10.1016/j.eclinm.2019.06.004. eCollection 2019 Jul.

5.

Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial.

Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RWJ, Dick AD, Ramanan AV.

Am J Ophthalmol. 2019 Jun 12. pii: S0002-9394(19)30274-0. doi: 10.1016/j.ajo.2019.06.007. [Epub ahead of print]

PMID:
31201796
6.

The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis.

Dimou P, Wright RD, Budge KL, Midgley A, Satchell SC, Peak M, Beresford MW.

Sci Rep. 2019 Jun 6;9(1):8348. doi: 10.1038/s41598-019-44868-y.

7.

Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

Ramanan AV, Hampson LV, Lythgoe H, Jones AP, Hardwick B, Hind H, Jacobs B, Vasileiou D, Wadsworth I, Ambrose N, Davidson J, Ferguson PJ, Herlin T, Kavirayani A, Killeen OG, Compeyrot-Lacassagne S, Laxer RM, Roderick M, Swart JF, Hedrich CM, Beresford MW.

PLoS One. 2019 Jun 5;14(6):e0215739. doi: 10.1371/journal.pone.0215739. eCollection 2019.

8.

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, Williamson PR, Hardwick B, Hickey H, Rainford N, Hickey G, Kolamunnage-Dona R, Culeddu G, Plumpton C, Wood E, Compeyrot-Lacassagne S, Woo P, Edelsten C, Beresford MW.

Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.

9.

The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients.

Rodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D.

Asian Pac J Allergy Immunol. 2019 Apr 23. doi: 10.12932/AP-211218-0465. [Epub ahead of print]

10.

Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients.

Abdelrahman N, Beresford MW, Leone V; UK Juvenile-onset Systemic Lupus Erythematosus Study Group.

Lupus. 2019 Apr;28(5):667-674. doi: 10.1177/0961203319840699. Epub 2019 Apr 3.

PMID:
30943853
11.

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).

Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H, Lee R, McKay A, Beresford MW; APTITUDE Trial Management Group.

BMC Rheumatol. 2018 Feb 27;2:4. doi: 10.1186/s41927-018-0010-2. eCollection 2018.

12.

European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.

Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW.

Rheumatology (Oxford). 2019 Sep 1;58(9):1607-1616. doi: 10.1093/rheumatology/kez041.

PMID:
30879080
13.

Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.

Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM.

Lupus. 2019 Apr;28(5):613-620. doi: 10.1177/0961203319836712. Epub 2019 Mar 14.

PMID:
30871425
14.

Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis.

Kearsley-Fleet L, Vicente González L, Steinke D, Davies R, De Cock D, Baildam E, Beresford MW, Foster HE, Southwood TR, Thomson W, Hyrich KL; Biologics for Children with Rheumatic Diseases (BCRD) Study and the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).

Rheumatology (Oxford). 2019 Mar 8. pii: kez048. doi: 10.1093/rheumatology/kez048. [Epub ahead of print]

15.

Reply.

Hughes DA, Culeddu G, Plumpton C, Wood E, Dick AD, Beresford MW, Ramanan AV.

Ophthalmology. 2019 Mar;126(3):e24-e25. doi: 10.1016/j.ophtha.2018.12.005. No abstract available.

PMID:
30803529
16.

Working together to deliver stratified medicine research effectively.

Attar SG, Poustie VJ, Smye SW, Beety JM, Hawcutt DB, Littlewood S, Oni L, Pirmohamed M, Beresford MW.

Br Med Bull. 2019 Mar 1;129(1):107-116. doi: 10.1093/bmb/ldz003. Review.

PMID:
30753334
17.

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.

Brunner HI, Holland MJ, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, Flores F, Goilav B, Avar Aydin PO, Wenderfer SE, Levy DM, Ravelli A, Khubchandani R, Avcin T, Klein-Gitelman MS, Ruperto N, Feldman BM, Ying J; Paediatric Rheumatology International Trial Organisation and Pediatric Rheumatology Collaborative Study Group.

Arthritis Care Res (Hoboken). 2019 May;71(5):579-590. doi: 10.1002/acr.23834.

PMID:
30680946
18.

The European network for care of children with paediatric rheumatic diseases: care across borders.

Dolezalova P, Anton J, Avcin T, Beresford MW, Brogan PA, Constantin T, Egert Y, Foeldvari I, Foster HE, Hentgen V, Kone-Paut I, Kuemmerle-Deschner JB, Lahdenne P, Magnusson B, Martini A, McCann L, Minden K, Ozen S, Schoemaker C, Quartier P, Ravelli A, Rumba-Rozenfelde I, Ruperto N, Vastert S, Wouters C, Zulian F, Wulffraat NM.

Rheumatology (Oxford). 2019 Jul 1;58(7):1188-1195. doi: 10.1093/rheumatology/key439.

PMID:
30668879
19.

European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative.

de Graeff N, Groot N, Brogan P, Ozen S, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW.

Rheumatology (Oxford). 2019 Apr 1;58(4):656-671. doi: 10.1093/rheumatology/key322.

PMID:
30535249
20.

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative.

de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Brogan P, Beresford MW.

Rheumatology (Oxford). 2019 Apr 1;58(4):672-682. doi: 10.1093/rheumatology/key344.

PMID:
30535127
21.

Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials.

Sherratt FC, Roper L, Stones SR, McErlane F, Peak M, Beresford MW, Foster H, Ramanan AV, Rooney M, Baildam E, Young B.

Pediatr Rheumatol Online J. 2018 Dec 4;16(1):76. doi: 10.1186/s12969-018-0293-2.

22.

Ophthalmology research in the UK's National Health Service: the structure and performance of the NIHR's Ophthalmology research portfolio.

Dawson SR, Linton E, Beicher K, Gale R, Patel P, Ghanchi F, Beresford MW, Poustie V, Chakravarthy U, Bourne RRA; NIHR Ophthalmology Specialty Group.

Eye (Lond). 2019 Apr;33(4):610-618. doi: 10.1038/s41433-018-0251-8. Epub 2018 Nov 20.

PMID:
30459469
23.

A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity.

Smith EMD, Eleuteri A, Goilav B, Lewandowski L, Phuti A, Rubinstein T, Wahezi D, Jones CA, Marks SD, Corkhill R, Pilkington C, Tullus K, Putterman C, Scott C, Fisher AC, Beresford MW.

Clin Immunol. 2019 Jan;198:71-78. doi: 10.1016/j.clim.2018.10.021. Epub 2018 Nov 2.

PMID:
30391651
24.

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.

Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, De Cock D, Foster HE, Southwood TR, Thomson W, Hyrich KL.

Rheumatology (Oxford). 2019 Feb 1;58(2):331-335. doi: 10.1093/rheumatology/key306.

25.

Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort.

Smith EMD, Lewandowski LB, Jorgensen AL, Phuti A, Nourse P, Scott C, Beresford MW.

Lupus. 2018 Dec;27(14):2190-2199. doi: 10.1177/0961203318808376. Epub 2018 Oct 22.

PMID:
30348048
26.

The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review.

Peterknecht E, Keasey MP, Beresford MW.

Lupus. 2018 Nov;27(13):2135-2145. doi: 10.1177/0961203318804879. Epub 2018 Oct 18.

PMID:
30336753
27.

Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.

Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV.

Ophthalmology. 2019 Mar;126(3):415-424. doi: 10.1016/j.ophtha.2018.09.043. Epub 2018 Oct 16.

PMID:
30336181
28.

Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus.

Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO).

J Rheumatol. 2019 Feb;46(2):190-197. doi: 10.3899/jrheum.180168. Epub 2018 Oct 1.

29.

Big data and stratified medicine: what does it mean for children?

Ding WY, Beresford MW, Saleem MA, Ramanan AV.

Arch Dis Child. 2019 Apr;104(4):389-394. doi: 10.1136/archdischild-2018-315125. Epub 2018 Sep 28. Review.

PMID:
30266876
30.

Clinical predictors of active LN development in children - evidence from the UK JSLE Cohort Study.

Smith EMD, Yin P, Jorgensen AL, Beresford MW.

Lupus. 2018 Nov;27(13):2020-2028. doi: 10.1177/0961203318801526. Epub 2018 Sep 23.

PMID:
30246602
31.

Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis.

Wright RD, Beresford MW.

Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1683-F1694. doi: 10.1152/ajprenal.00512.2017. Epub 2018 Sep 12.

32.

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.

Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, Southwood TR, Thomson W, Hyrich KL.

Rheumatology (Oxford). 2019 Jan 1;58(1):94-102. doi: 10.1093/rheumatology/key262.

33.

Juvenile-onset systemic lupus erythematosus (jSLE) - Pathophysiological concepts and treatment options.

Hedrich CM, Smith EMD, Beresford MW.

Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi: 10.1016/j.berh.2018.02.001. Epub 2018 Mar 1. Review.

PMID:
29773269
34.

Preface: Recent advances in autoimmune and auto-inflammatory diseases in childhood.

Ramanan AV, Beresford MW.

Best Pract Res Clin Rheumatol. 2017 Aug;31(4):439-440. doi: 10.1016/j.berh.2018.03.001. Epub 2018 Apr 19. No abstract available.

PMID:
29773265
35.

American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus.

Brunner HI, Holland M, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, Flores F, Goilav B, Wenderfer SE, Levy DM, Ravelli A, Khunchandani R, Avcin T, Klein-Gitelman MS, Feldman BM, Ruperto N, Ying J; PRCSG and PRINTO Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):813-822. doi: 10.1002/acr.23557. Epub 2018 Apr 25.

36.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
37.

Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Suwanchote S, Rachayon M, Rodsaward P, Wongpiyabovorn J, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D.

Clin Rheumatol. 2018 Apr;37(4):875-884. doi: 10.1007/s10067-018-4062-x. Epub 2018 Mar 10. Review.

PMID:
29525845
38.

Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study.

Smith EMD, Yin P, Jorgensen AL, Beresford MW; UK JSLE Study Group.

Pediatr Rheumatol Online J. 2018 Feb 21;16(1):14. doi: 10.1186/s12969-018-0230-4.

39.

Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus.

Holland MJ, Beresford MW, Feldman BM, Huggins J, Norambuena X, Silva CA, Susic G, Sztajnbok F, Uziel Y, Appenzeller S, Ardoin SP, Avcin T, Flores F, Goilav B, Khubchandani R, Klein-Gitelman M, Levy D, Ravelli A, Wenderfer SE, Ying J, Ruperto N, Brunner HI; PRINTO and PRCSG Investigators.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1621-1629. doi: 10.1002/acr.23531.

40.

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

Lawrie TA, Green JT, Beresford M, Wedlake L, Burden S, Davidson SE, Lal S, Henson CC, Andreyev HJN.

Cochrane Database Syst Rev. 2018 Jan 23;1:CD012529. doi: 10.1002/14651858.CD012529.pub2. Review.

41.

The transition of adolescents with juvenile idiopathic arthritis or epilepsy from paediatric health-care services to adult health-care services: A scoping review of the literature and a synthesis of the evidence.

Burke L, Kirkham J, Arnott J, Gray V, Peak M, Beresford MW.

J Child Health Care. 2018 Sep;22(3):332-358. doi: 10.1177/1367493517753330. Epub 2018 Jan 21. Review.

PMID:
29355024
42.

Paediatric rheumatology in 2017: Child-centred research is the key to progress.

Beresford MW, Ramanan AV.

Nat Rev Rheumatol. 2018 Feb;14(2):69-70. doi: 10.1038/nrrheum.2017.214. Epub 2018 Jan 11. Review. No abstract available.

PMID:
29323342
43.

Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes.

Ramanathan K, Glaser A, Lythgoe H, Ong J, Beresford MW, Midgley A, Wright HL.

Rheumatology (Oxford). 2018 Mar 1;57(3):488-498. doi: 10.1093/rheumatology/kex441.

PMID:
29240923
44.

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.

Ann Rheum Dis. 2018 Feb;77(2):241-250. doi: 10.1136/annrheumdis-2017-212141. Epub 2017 Oct 30.

45.

Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.

Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE.

Rheumatology (Oxford). 2018 Feb 1;57(2):398-401. doi: 10.1093/rheumatology/kex382. No abstract available.

PMID:
29077971
46.

Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.

Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, Avcin T, Martini A, Koné-Paut I, Uziel Y, Ravelli A, Wouters C, Shaw D, Özen S, Eikelberg A, Prakken BJ, Ruperto N, Horneff G, Constantin T, Beresford MW, Sikken M, Foster HE, Haug I, Schuller S, Jägle C, Benseler SM.

Ann Rheum Dis. 2018 Mar;77(3):319-327. doi: 10.1136/annrheumdis-2017-211904. Epub 2017 Oct 11. Review.

PMID:
29021237
47.

European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.

Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Özen S, Pilkington CA, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert BJ, Wulffraat NM, Beresford MW, Kamphuis S.

Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.

PMID:
28877866
48.

Adalimumab for Uveitis in Juvenile Idiopathic Arthritis.

Ramanan AV, Dick AD, Beresford MW.

N Engl J Med. 2017 Aug 24;377(8):789-790. doi: 10.1056/NEJMc1708646. No abstract available.

PMID:
28834482
49.

Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.

Thompson AL, Sarmah P, Beresford MJ, Jefferies ER.

BJU Int. 2017 Dec;120(6):751-754. doi: 10.1111/bju.13990. Epub 2017 Sep 5. Review. No abstract available.

50.

Holistic and consumer-centric assessment of beer: A multi-measurement approach.

Jaeger SR, Cardello AV, Chheang SL, Beresford MK, Hedderley DI, Pineau B.

Food Res Int. 2017 Sep;99(Pt 1):287-297. doi: 10.1016/j.foodres.2017.05.004. Epub 2017 May 6.

PMID:
28784485

Supplemental Content

Loading ...
Support Center